LAVAL, Quebec–(BUSINESS WIRE)– #Bioavailability–Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials. Vibegron is a beta-3 adrenergic receptor (β3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. The approval was announced by Urovant Sciences on December 23, 2020. “We take tremendous pride in contributing to the FDA approval of much-ne
Source link
Comments are closed, but trackbacks and pingbacks are open.